Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences common stock repurchases — Cash paid ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Cash Flows
Latest, Q2 2026
355
Period ended Jun 30, 2026
Change on a year earlier
-32.6%
527 in Q2 2025
History
50 quarters
Since Q1 2014
Sources
41
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Common stock repurchases — Cash paid ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 355 | -32.6% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 419 | -42.6% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 230 | -34.3% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 435 | +45.0% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 527 | +427.0% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 730 | +82.5% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 350 | +133.3% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 300 | 0.0% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 100 | -33.3% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 400 | 0.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 150 | -81.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 300 | +66.7% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 150 | +108.3% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 400 | +13.6% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 792 | +1,516.3% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 180 | +24.1% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 72 | +67.4% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 352 | +13.9% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 49 | – | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 145 | -27.9% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 43 | -20.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 309 | -76.7% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 0 | -100.0% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 201 | -9.5% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 54 | -90.8% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,328 | +59.2% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 105 | -89.1% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 222 | -50.6% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 588 | +30.7% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 834 | -19.7% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 962 | +807.5% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 449 | +193.5% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 450 | +246.2% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,039 | +83.9% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 106 | -89.4% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 153 | -84.7% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 130 | -87.0% | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 565 | -92.9% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,000 | -67.2% | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,000 | -67.2% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,001 | +11.2% | Form 10-Q (filed 2017-08-07) ↗ |
| Q1 2016 | Mar 31, 2016 | 8,000 | +166.6% | Form 10-Q (filed 2017-05-10) ↗ |
| Q4 2015 | Dec 31, 2015 | 3,051 | +52.5% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2015 | Sep 30, 2015 | 3,050 | +79.4% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2015 | Jun 30, 2015 | 900 | -25.0% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2015 | Mar 31, 2015 | 3,001 | +566.9% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2014 | Dec 31, 2014 | 2,001 | – | Form 10-K (filed 2017-02-27) ↗ |
| Q3 2014 | Sep 30, 2014 | 1,700 | – | SEC Filing ↗ |
| Q2 2014 | Jun 30, 2014 | 1,200 | – | SEC Filing ↗ |
| Q1 2014 | Mar 31, 2014 | 450 | – | Form 10-Q (filed 2015-05-08) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Common stock repurchases — Cash paid ($M) ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/cap_buyback_cash
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.